Christina Rossi

Ms. Rossi joined the board of Xilio Therapeutics with over 20 years of experience in the pharmaceutical and biotechnology industries. She currently serves as Chief Commercial Officer of Blueprint Medicines. At Blueprint Medicines, Ms. Rossi has played a critical role in the U.S. launches of AYVAKIT™ and GAVRETO®. Before her time at Blueprint, she spent six years at Sanofi Genzyme in various roles leading launches of new therapies, and optimized operations to expand patient access, including Multiple Sclerosis (MS) Business Unit Head of North America; Vice President of MS Sales; and Vice President of MS Patient and Provider Services. Prior to Sanofi Genzyme, Ms. Rossi lead brands and a biosimilar-focused venture at Biogen, Inc. She also consulted within Boston Consulting Group’s healthcare practice. Ms. Rossi holds a B.S. in Biology from Duke University and an M.B.A. from Harvard Business School.